Trial Profile
Effect of dapagliflozin, the sodium-glucose-cotransporter-2 (SGLT2) inhibitor, on fibroblast growth factor 21 (FGF21), a novel hepatokine and myokine, in Japanese patients of type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 11 Jun 2020 Status changed from active, no longer recruiting to completed.
- 16 Sep 2017 Status changed to active, no longer recruiting.
- 24 May 2016 New trial record